<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858555</url>
  </required_header>
  <id_info>
    <org_study_id>I16017_1 (Biostaging)</org_study_id>
    <nct_id>NCT04858555</nct_id>
  </id_info>
  <brief_title>Staging System in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>Biostaging</acronym>
  <official_title>Staging System in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently two staging systems have been proposed for amyotrophic lateral sclerosis (ALS),&#xD;
      based on clinical milestones The King's college clinical staging system (1) and ALS&#xD;
      Milano-Torino Staging (ALS-MITOS) (2). Further research to validate and develop an accurate&#xD;
      staging system in different populations will improve our understanding of its pathogenesis,&#xD;
      disease activity and progression.&#xD;
&#xD;
      General objective : To validate the two previously proposed staging system and to test the&#xD;
      interest of considering Neurofilament biomarkers in these systems.&#xD;
&#xD;
      Specific objectives: 1) To validate the two classification systems in an independent cohort&#xD;
      of patients with ALS followed-up in the ALS expert center of Limoges (France) 2) To assess&#xD;
      the interest of Nf biomarkers to predict neurological decline&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a rare, fatal neurodegenerative disease of the human&#xD;
      motor system. Recently two new staging systems have been proposed for ALS, based on clinical&#xD;
      milestones related also to the spreading pattern of the disease (1,2). Furthermore, biomarker&#xD;
      development is still an essential component of future therapeutic development in ALS. Thus,&#xD;
      it is also important to acknowledge the value of biomarker research in supporting or&#xD;
      revealing fundamental pathophysiological mechanisms in ALS.&#xD;
&#xD;
      The proposed staging systems: have been recently tested in two independent cohorts (3,4) with&#xD;
      results that were not fully consistent (ii) did not considered the potential value of&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To validate the two previously proposed staging system and to develop an accurate staging system in ALS considering Neurofilament (Nf) biomarkers.</measure>
    <time_frame>2 years</time_frame>
    <description>To validate the two previously proposed staging system and to develop an accurate staging system in ALS considering Neurofilament (Nf) biomarkers</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be collected from ALS incident cases. Neurofilaments levels will be&#xD;
      determined in the plasma using ELISA Method&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ALS, followed-up in the ALS expert center of Limoges university Hospital&#xD;
        (France).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS cases recruited for retrospectively (between) 2007 to 2016 for the retrospective&#xD;
             cohort&#xD;
&#xD;
          -  ALS cases recruited for prospectively by the ALS expert center of Limoges for one&#xD;
             year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous neurosurgical operations&#xD;
&#xD;
          -  A recent history of neurotrauma&#xD;
&#xD;
          -  Peripheral neuropathies&#xD;
&#xD;
          -  ALS/frontotemporal dementia (ALS/FTD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Couratier, Pr</last_name>
    <phone>00335 55 05 65 61</phone>
    <email>Philippe.Couratier@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaime LUNA, PhD</last_name>
    <phone>00335 55 05 65 61</phone>
    <email>jaimeandreslunam@gmail.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Staging</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

